Protein arginine-methyltransferase 1 (PRMT1): a new pharmacological target in cholangiocarcinoma
Emiliana Valbuena-Goiricelaya, Jasmin Elurbide, Maria Ujue Latasa, Amaya López-Pascual, Iker Uriarte, Leticia Colyn, Patrícia Inácio, Robert Arnes‐Benito, Elena Adán-Villaescusa, Borja Castelló-Uribe, Barbara Franceschini, Flavio Milana, Pavel Strnad, Soňa Fraňková, Eva Sticová, , Matias Antonio Avila
This study identifies PRMT1 as a critical driver of cholangiocarcinoma growth and immune evasion, showing its inhibition enhances antitumor immunity and synergizes with immunotherapy.
bioRxiv · May 29, 2026 · PreprintCancer Biology